Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30918718 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL539900 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL30918715 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL20929165 | 0.85 | CHRM2 (0.44) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL3741129 | 0.85 | CHRM2 (0.48) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL3733204 | 0.83 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL3733352 | 0.83 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL483259 | 0.77 | CHRM2 (0.43) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL20406585 | 0.77 | CHRM2 (0.43) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL26663232 | 0.76 | CHRM2 (0.47) | CHRM2CHRM1CHRM3NR1H2KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654824-B2 | 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use | GENENTECH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190119246-A1 | 2-AZABICYCLO[3.1.0]HEXAN-3-ONE DERIVATIVES AND METHODS OF USE | GENENTECH, INC. (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654824-B2 | 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use | NFKB2, NFKBIA, NFKB1 | CHRM2 508/4885CHRM1 545/4885CHRM3 2295/4885 |
| US-20190119246-A1 | 2-AZABICYCLO[3.1.0]HEXAN-3-ONE DERIVATIVES AND METHODS OF USE | NFKB2, NFKBIA, NFKB1 | CHRM2 508/4885CHRM1 545/4885CHRM3 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.